Global Flu RNA Vaccines Market

Flu RNA Vaccines Comprehensive Study by Application (Hospitals, Emergency Departments, Clinics, Others), End Users (Adults, Kids), Sales (Hospitals, Retail Pharmacy Stores), Usages (Infectious Disease, Flu, Others) Players and Region - Global Market Outlook to 2026

Flu RNA Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Flu RNA Vaccines Market Scope
The Vaccine is nothing but biological preparation that provides an active immunity booster for a particular infection. They stimulate the body’s immune system to recognize a disease-causing microorganism as a danger and then devastate it. Its administration is known as vaccination, the most effective method of preventing infectious diseases. RNA-based vaccines, which are relatively fast and inexpensive to develop and maybe safer to use may proclaim quicker control over the spread of infectious illnesses, including COVID-19.

The Flu RNA Vaccines market study is segmented, by Application (Hospitals, Emergency Departments, Clinics and Others) and major geographies with country level break-up.

The rising number of players expected to enter the global market is predicted to enhance the competition level as well as encourage the growth of the overall market in the near future. Players are anticipated to focus on the development of new compounds, which is likely to encourage the growth of the global market throughout the forecast period. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Flu RNA Vaccines market throughout the predicted period.

Alnylam Pharmaceuticals, Inc. (United States), Arbutus Biopharma Corp. (Canada), Arrowhead Pharmaceuticals, Inc. (United States), BioNTech AG (Germany), CureVac AG (Germany), Dicerna Pharmaceuticals, Inc. (United States), Regulus Therapeutics, Inc. (United States) and Marina Biotech, Inc (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Pfizer (United States), Moderna (United States), GlaxoSmithKline (United Kingdom) and Translate Bio (United States)`.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Flu RNA Vaccines market by Type, Application and Region.

On the basis of geography, the market of Flu RNA Vaccines has been segmented into South America (Brazil, Argentina, Chile, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Singapore, Indonesia, Thailand, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Spain, Sweden, Belgium, Finland, Denmark, Russia, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Market Leaders and their expansionary development strategies
In March 2020, Pfizer and BioNTech had announced a strategic collaboration to advance the development of mRNA vaccine for coronavirus infection. This would fasten the development process and offer a competitive advantage to the company. and In August 2020, Novavax had signed licensing agreement with Serum Institute of India for the development and commercialization of its novel COVID-19 vaccine candidate NVX-CoV2373 in low and middle-income countries along with India. This will boost the revenue of the company.
In May 2020, AstraZeneca had received over USD 1 billion from the US Biomedical Advanced Research and Development Authority (BARDA) for the development and manufacturing of vaccines pertaining to COVID-19. Increasing investments will enhance the firm’s growth potential in the market.


Market Trend
  • Increasing R&D in Pharmaceutical Setor

Market Drivers
  • Increasing Disposable Income
  • Increasing Infectious Disease like Covid-19

Opportunities
  • Increasing Government Initiatives and Promotion of Health Related Vaccine

Restraints
  • Side Effect of the Vaccine
  • High Cost of the Product

Challenges
  • Stringent Government Regulation


Key Target Audience
Vaccine Manufacturers, Industry Association, Downstream Vendors, Marketing & Consulting firms, Venture Capitalists, Government & Regulatory Bodies and Traders/Suppliers & Distributors

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Emergency Departments
  • Clinics
  • Others
By End Users
  • Adults
  • Kids

By Sales
  • Hospitals
  • Retail Pharmacy Stores

By Usages
  • Infectious Disease
  • Flu
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Indonesia
    • Thailand
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Spain
    • Sweden
    • Belgium
    • Finland
    • Denmark
    • Russia
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Disposable Income
      • 3.2.2. Increasing Infectious Disease like Covid-19
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulation
    • 3.4. Market Trends
      • 3.4.1. Increasing R&D in Pharmaceutical Setor
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Flu RNA Vaccines, by Application, End Users, Sales, Usages and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Flu RNA Vaccines (Value)
      • 5.2.1. Global Flu RNA Vaccines by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Emergency Departments
        • 5.2.1.3. Clinics
        • 5.2.1.4. Others
      • 5.2.2. Global Flu RNA Vaccines by: End Users (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Kids
      • 5.2.3. Global Flu RNA Vaccines by: Sales (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Retail Pharmacy Stores
      • 5.2.4. Global Flu RNA Vaccines by: Usages (Value)
        • 5.2.4.1. Infectious Disease
        • 5.2.4.2. Flu
        • 5.2.4.3. Others
      • 5.2.5. Global Flu RNA Vaccines Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Chile
          • 5.2.5.1.4. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Singapore
          • 5.2.5.2.6. Indonesia
          • 5.2.5.2.7. Thailand
          • 5.2.5.2.8. Australia
          • 5.2.5.2.9. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Spain
          • 5.2.5.3.7. Sweden
          • 5.2.5.3.8. Belgium
          • 5.2.5.3.9. Finland
          • 5.2.5.3.10. Denmark
          • 5.2.5.3.11. Russia
          • 5.2.5.3.12. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Flu RNA Vaccines (Volume)
      • 5.3.1. Global Flu RNA Vaccines by: Application (Volume)
        • 5.3.1.1. Hospitals
        • 5.3.1.2. Emergency Departments
        • 5.3.1.3. Clinics
        • 5.3.1.4. Others
      • 5.3.2. Global Flu RNA Vaccines by: End Users (Volume)
        • 5.3.2.1. Adults
        • 5.3.2.2. Kids
      • 5.3.3. Global Flu RNA Vaccines by: Sales (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Retail Pharmacy Stores
      • 5.3.4. Global Flu RNA Vaccines by: Usages (Volume)
        • 5.3.4.1. Infectious Disease
        • 5.3.4.2. Flu
        • 5.3.4.3. Others
      • 5.3.5. Global Flu RNA Vaccines Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Chile
          • 5.3.5.1.4. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Singapore
          • 5.3.5.2.6. Indonesia
          • 5.3.5.2.7. Thailand
          • 5.3.5.2.8. Australia
          • 5.3.5.2.9. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Spain
          • 5.3.5.3.7. Sweden
          • 5.3.5.3.8. Belgium
          • 5.3.5.3.9. Finland
          • 5.3.5.3.10. Denmark
          • 5.3.5.3.11. Russia
          • 5.3.5.3.12. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Flu RNA Vaccines (Price)
  • 6. Flu RNA Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Alnylam Pharmaceuticals, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Arbutus Biopharma Corp. (Canada)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Arrowhead Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BioNTech AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. CureVac AG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Dicerna Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Regulus Therapeutics, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Marina Biotech, Inc (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Flu RNA Vaccines Sale, by Application, End Users, Sales, Usages and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Flu RNA Vaccines (Value)
      • 7.2.1. Global Flu RNA Vaccines by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Emergency Departments
        • 7.2.1.3. Clinics
        • 7.2.1.4. Others
      • 7.2.2. Global Flu RNA Vaccines by: End Users (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Kids
      • 7.2.3. Global Flu RNA Vaccines by: Sales (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Retail Pharmacy Stores
      • 7.2.4. Global Flu RNA Vaccines by: Usages (Value)
        • 7.2.4.1. Infectious Disease
        • 7.2.4.2. Flu
        • 7.2.4.3. Others
      • 7.2.5. Global Flu RNA Vaccines Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Chile
          • 7.2.5.1.4. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Singapore
          • 7.2.5.2.6. Indonesia
          • 7.2.5.2.7. Thailand
          • 7.2.5.2.8. Australia
          • 7.2.5.2.9. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Spain
          • 7.2.5.3.7. Sweden
          • 7.2.5.3.8. Belgium
          • 7.2.5.3.9. Finland
          • 7.2.5.3.10. Denmark
          • 7.2.5.3.11. Russia
          • 7.2.5.3.12. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Flu RNA Vaccines (Volume)
      • 7.3.1. Global Flu RNA Vaccines by: Application (Volume)
        • 7.3.1.1. Hospitals
        • 7.3.1.2. Emergency Departments
        • 7.3.1.3. Clinics
        • 7.3.1.4. Others
      • 7.3.2. Global Flu RNA Vaccines by: End Users (Volume)
        • 7.3.2.1. Adults
        • 7.3.2.2. Kids
      • 7.3.3. Global Flu RNA Vaccines by: Sales (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Retail Pharmacy Stores
      • 7.3.4. Global Flu RNA Vaccines by: Usages (Volume)
        • 7.3.4.1. Infectious Disease
        • 7.3.4.2. Flu
        • 7.3.4.3. Others
      • 7.3.5. Global Flu RNA Vaccines Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Chile
          • 7.3.5.1.4. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Singapore
          • 7.3.5.2.6. Indonesia
          • 7.3.5.2.7. Thailand
          • 7.3.5.2.8. Australia
          • 7.3.5.2.9. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Spain
          • 7.3.5.3.7. Sweden
          • 7.3.5.3.8. Belgium
          • 7.3.5.3.9. Finland
          • 7.3.5.3.10. Denmark
          • 7.3.5.3.11. Russia
          • 7.3.5.3.12. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Flu RNA Vaccines (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Flu RNA Vaccines: by Application(USD Million)
  • Table 2. Flu RNA Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 3. Flu RNA Vaccines Emergency Departments , by Region USD Million (2015-2020)
  • Table 4. Flu RNA Vaccines Clinics , by Region USD Million (2015-2020)
  • Table 5. Flu RNA Vaccines Others , by Region USD Million (2015-2020)
  • Table 6. Flu RNA Vaccines: by End Users(USD Million)
  • Table 7. Flu RNA Vaccines Adults , by Region USD Million (2015-2020)
  • Table 8. Flu RNA Vaccines Kids , by Region USD Million (2015-2020)
  • Table 9. Flu RNA Vaccines: by Sales(USD Million)
  • Table 10. Flu RNA Vaccines Hospitals , by Region USD Million (2015-2020)
  • Table 11. Flu RNA Vaccines Retail Pharmacy Stores , by Region USD Million (2015-2020)
  • Table 12. Flu RNA Vaccines: by Usages(USD Million)
  • Table 13. Flu RNA Vaccines Infectious Disease , by Region USD Million (2015-2020)
  • Table 14. Flu RNA Vaccines Flu , by Region USD Million (2015-2020)
  • Table 15. Flu RNA Vaccines Others , by Region USD Million (2015-2020)
  • Table 16. South America Flu RNA Vaccines, by Country USD Million (2015-2020)
  • Table 17. South America Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 18. South America Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 19. South America Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 20. South America Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 21. Brazil Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 22. Brazil Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 23. Brazil Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 24. Brazil Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 25. Argentina Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 26. Argentina Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 27. Argentina Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 28. Argentina Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 29. Chile Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 30. Chile Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 31. Chile Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 32. Chile Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 33. Rest of South America Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 34. Rest of South America Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 35. Rest of South America Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 36. Rest of South America Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 37. Asia Pacific Flu RNA Vaccines, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 39. Asia Pacific Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 40. Asia Pacific Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 41. Asia Pacific Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 42. China Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 43. China Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 44. China Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 45. China Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 46. Japan Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 47. Japan Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 48. Japan Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 49. Japan Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 50. India Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 51. India Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 52. India Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 53. India Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 54. South Korea Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 55. South Korea Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 56. South Korea Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 57. South Korea Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 58. Singapore Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 59. Singapore Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 60. Singapore Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 61. Singapore Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 62. Indonesia Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 63. Indonesia Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 64. Indonesia Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 65. Indonesia Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 66. Thailand Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 67. Thailand Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 68. Thailand Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 69. Thailand Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 70. Australia Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 71. Australia Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 72. Australia Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 73. Australia Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 74. Rest of Asia-Pacific Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 75. Rest of Asia-Pacific Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 76. Rest of Asia-Pacific Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 77. Rest of Asia-Pacific Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 78. Europe Flu RNA Vaccines, by Country USD Million (2015-2020)
  • Table 79. Europe Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 80. Europe Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 81. Europe Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 82. Europe Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 83. Germany Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 84. Germany Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 85. Germany Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 86. Germany Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 87. France Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 88. France Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 89. France Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 90. France Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 91. Italy Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 92. Italy Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 93. Italy Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 94. Italy Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 95. United Kingdom Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 96. United Kingdom Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 97. United Kingdom Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 98. United Kingdom Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 99. Netherlands Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 100. Netherlands Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 101. Netherlands Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 102. Netherlands Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 103. Spain Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 104. Spain Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 105. Spain Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 106. Spain Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 107. Sweden Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 108. Sweden Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 109. Sweden Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 110. Sweden Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 111. Belgium Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 112. Belgium Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 113. Belgium Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 114. Belgium Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 115. Finland Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 116. Finland Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 117. Finland Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 118. Finland Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 119. Denmark Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 120. Denmark Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 121. Denmark Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 122. Denmark Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 123. Russia Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 124. Russia Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 125. Russia Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 126. Russia Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 127. Rest of Europe Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 128. Rest of Europe Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 129. Rest of Europe Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 130. Rest of Europe Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 131. MEA Flu RNA Vaccines, by Country USD Million (2015-2020)
  • Table 132. MEA Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 133. MEA Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 134. MEA Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 135. MEA Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 136. Middle East Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 137. Middle East Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 138. Middle East Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 139. Middle East Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 140. Africa Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 141. Africa Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 142. Africa Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 143. Africa Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 144. North America Flu RNA Vaccines, by Country USD Million (2015-2020)
  • Table 145. North America Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 146. North America Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 147. North America Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 148. North America Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 149. United States Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 150. United States Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 151. United States Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 152. United States Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 153. Canada Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 154. Canada Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 155. Canada Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 156. Canada Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 157. Mexico Flu RNA Vaccines, by Application USD Million (2015-2020)
  • Table 158. Mexico Flu RNA Vaccines, by End Users USD Million (2015-2020)
  • Table 159. Mexico Flu RNA Vaccines, by Sales USD Million (2015-2020)
  • Table 160. Mexico Flu RNA Vaccines, by Usages USD Million (2015-2020)
  • Table 161. Flu RNA Vaccines Sales: by Application(K Units)
  • Table 162. Flu RNA Vaccines Sales Hospitals , by Region K Units (2015-2020)
  • Table 163. Flu RNA Vaccines Sales Emergency Departments , by Region K Units (2015-2020)
  • Table 164. Flu RNA Vaccines Sales Clinics , by Region K Units (2015-2020)
  • Table 165. Flu RNA Vaccines Sales Others , by Region K Units (2015-2020)
  • Table 166. Flu RNA Vaccines Sales: by End Users(K Units)
  • Table 167. Flu RNA Vaccines Sales Adults , by Region K Units (2015-2020)
  • Table 168. Flu RNA Vaccines Sales Kids , by Region K Units (2015-2020)
  • Table 169. Flu RNA Vaccines Sales: by Sales(K Units)
  • Table 170. Flu RNA Vaccines Sales Hospitals , by Region K Units (2015-2020)
  • Table 171. Flu RNA Vaccines Sales Retail Pharmacy Stores , by Region K Units (2015-2020)
  • Table 172. Flu RNA Vaccines Sales: by Usages(K Units)
  • Table 173. Flu RNA Vaccines Sales Infectious Disease , by Region K Units (2015-2020)
  • Table 174. Flu RNA Vaccines Sales Flu , by Region K Units (2015-2020)
  • Table 175. Flu RNA Vaccines Sales Others , by Region K Units (2015-2020)
  • Table 176. South America Flu RNA Vaccines Sales, by Country K Units (2015-2020)
  • Table 177. South America Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 178. South America Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 179. South America Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 180. South America Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 181. Brazil Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 182. Brazil Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 183. Brazil Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 184. Brazil Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 185. Argentina Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 186. Argentina Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 187. Argentina Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 188. Argentina Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 189. Chile Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 190. Chile Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 191. Chile Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 192. Chile Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 193. Rest of South America Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 194. Rest of South America Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 195. Rest of South America Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 196. Rest of South America Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 197. Asia Pacific Flu RNA Vaccines Sales, by Country K Units (2015-2020)
  • Table 198. Asia Pacific Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 199. Asia Pacific Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 200. Asia Pacific Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 201. Asia Pacific Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 202. China Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 203. China Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 204. China Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 205. China Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 206. Japan Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 207. Japan Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 208. Japan Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 209. Japan Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 210. India Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 211. India Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 212. India Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 213. India Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 214. South Korea Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 215. South Korea Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 216. South Korea Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 217. South Korea Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 218. Singapore Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 219. Singapore Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 220. Singapore Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 221. Singapore Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 222. Indonesia Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 223. Indonesia Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 224. Indonesia Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 225. Indonesia Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 226. Thailand Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 227. Thailand Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 228. Thailand Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 229. Thailand Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 230. Australia Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 231. Australia Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 232. Australia Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 233. Australia Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 234. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 235. Rest of Asia-Pacific Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 236. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 237. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 238. Europe Flu RNA Vaccines Sales, by Country K Units (2015-2020)
  • Table 239. Europe Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 240. Europe Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 241. Europe Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 242. Europe Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 243. Germany Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 244. Germany Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 245. Germany Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 246. Germany Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 247. France Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 248. France Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 249. France Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 250. France Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 251. Italy Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 252. Italy Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 253. Italy Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 254. Italy Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 255. United Kingdom Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 256. United Kingdom Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 257. United Kingdom Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 258. United Kingdom Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 259. Netherlands Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 260. Netherlands Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 261. Netherlands Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 262. Netherlands Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 263. Spain Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 264. Spain Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 265. Spain Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 266. Spain Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 267. Sweden Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 268. Sweden Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 269. Sweden Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 270. Sweden Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 271. Belgium Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 272. Belgium Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 273. Belgium Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 274. Belgium Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 275. Finland Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 276. Finland Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 277. Finland Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 278. Finland Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 279. Denmark Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 280. Denmark Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 281. Denmark Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 282. Denmark Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 283. Russia Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 284. Russia Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 285. Russia Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 286. Russia Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 287. Rest of Europe Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 288. Rest of Europe Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 289. Rest of Europe Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 290. Rest of Europe Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 291. MEA Flu RNA Vaccines Sales, by Country K Units (2015-2020)
  • Table 292. MEA Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 293. MEA Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 294. MEA Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 295. MEA Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 296. Middle East Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 297. Middle East Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 298. Middle East Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 299. Middle East Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 300. Africa Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 301. Africa Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 302. Africa Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 303. Africa Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 304. North America Flu RNA Vaccines Sales, by Country K Units (2015-2020)
  • Table 305. North America Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 306. North America Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 307. North America Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 308. North America Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 309. United States Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 310. United States Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 311. United States Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 312. United States Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 313. Canada Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 314. Canada Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 315. Canada Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 316. Canada Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 317. Mexico Flu RNA Vaccines Sales, by Application K Units (2015-2020)
  • Table 318. Mexico Flu RNA Vaccines Sales, by End Users K Units (2015-2020)
  • Table 319. Mexico Flu RNA Vaccines Sales, by Sales K Units (2015-2020)
  • Table 320. Mexico Flu RNA Vaccines Sales, by Usages K Units (2015-2020)
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Flu RNA Vaccines: by Application(USD Million)
  • Table 330. Flu RNA Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 331. Flu RNA Vaccines Emergency Departments , by Region USD Million (2021-2026)
  • Table 332. Flu RNA Vaccines Clinics , by Region USD Million (2021-2026)
  • Table 333. Flu RNA Vaccines Others , by Region USD Million (2021-2026)
  • Table 334. Flu RNA Vaccines: by End Users(USD Million)
  • Table 335. Flu RNA Vaccines Adults , by Region USD Million (2021-2026)
  • Table 336. Flu RNA Vaccines Kids , by Region USD Million (2021-2026)
  • Table 337. Flu RNA Vaccines: by Sales(USD Million)
  • Table 338. Flu RNA Vaccines Hospitals , by Region USD Million (2021-2026)
  • Table 339. Flu RNA Vaccines Retail Pharmacy Stores , by Region USD Million (2021-2026)
  • Table 340. Flu RNA Vaccines: by Usages(USD Million)
  • Table 341. Flu RNA Vaccines Infectious Disease , by Region USD Million (2021-2026)
  • Table 342. Flu RNA Vaccines Flu , by Region USD Million (2021-2026)
  • Table 343. Flu RNA Vaccines Others , by Region USD Million (2021-2026)
  • Table 344. South America Flu RNA Vaccines, by Country USD Million (2021-2026)
  • Table 345. South America Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 346. South America Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 347. South America Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 348. South America Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 349. Brazil Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 350. Brazil Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 351. Brazil Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 352. Brazil Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 353. Argentina Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 354. Argentina Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 355. Argentina Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 356. Argentina Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 357. Chile Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 358. Chile Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 359. Chile Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 360. Chile Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 361. Rest of South America Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 362. Rest of South America Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 363. Rest of South America Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 364. Rest of South America Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 365. Asia Pacific Flu RNA Vaccines, by Country USD Million (2021-2026)
  • Table 366. Asia Pacific Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 367. Asia Pacific Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 368. Asia Pacific Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 369. Asia Pacific Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 370. China Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 371. China Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 372. China Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 373. China Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 374. Japan Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 375. Japan Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 376. Japan Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 377. Japan Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 378. India Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 379. India Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 380. India Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 381. India Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 382. South Korea Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 383. South Korea Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 384. South Korea Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 385. South Korea Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 386. Singapore Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 387. Singapore Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 388. Singapore Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 389. Singapore Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 390. Indonesia Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 391. Indonesia Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 392. Indonesia Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 393. Indonesia Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 394. Thailand Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 395. Thailand Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 396. Thailand Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 397. Thailand Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 398. Australia Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 399. Australia Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 400. Australia Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 401. Australia Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 402. Rest of Asia-Pacific Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 403. Rest of Asia-Pacific Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 404. Rest of Asia-Pacific Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 405. Rest of Asia-Pacific Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 406. Europe Flu RNA Vaccines, by Country USD Million (2021-2026)
  • Table 407. Europe Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 408. Europe Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 409. Europe Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 410. Europe Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 411. Germany Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 412. Germany Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 413. Germany Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 414. Germany Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 415. France Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 416. France Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 417. France Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 418. France Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 419. Italy Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 420. Italy Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 421. Italy Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 422. Italy Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 423. United Kingdom Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 424. United Kingdom Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 425. United Kingdom Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 426. United Kingdom Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 427. Netherlands Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 428. Netherlands Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 429. Netherlands Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 430. Netherlands Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 431. Spain Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 432. Spain Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 433. Spain Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 434. Spain Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 435. Sweden Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 436. Sweden Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 437. Sweden Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 438. Sweden Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 439. Belgium Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 440. Belgium Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 441. Belgium Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 442. Belgium Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 443. Finland Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 444. Finland Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 445. Finland Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 446. Finland Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 447. Denmark Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 448. Denmark Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 449. Denmark Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 450. Denmark Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 451. Russia Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 452. Russia Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 453. Russia Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 454. Russia Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 455. Rest of Europe Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 456. Rest of Europe Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 457. Rest of Europe Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 458. Rest of Europe Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 459. MEA Flu RNA Vaccines, by Country USD Million (2021-2026)
  • Table 460. MEA Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 461. MEA Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 462. MEA Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 463. MEA Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 464. Middle East Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 465. Middle East Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 466. Middle East Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 467. Middle East Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 468. Africa Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 469. Africa Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 470. Africa Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 471. Africa Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 472. North America Flu RNA Vaccines, by Country USD Million (2021-2026)
  • Table 473. North America Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 474. North America Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 475. North America Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 476. North America Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 477. United States Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 478. United States Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 479. United States Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 480. United States Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 481. Canada Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 482. Canada Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 483. Canada Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 484. Canada Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 485. Mexico Flu RNA Vaccines, by Application USD Million (2021-2026)
  • Table 486. Mexico Flu RNA Vaccines, by End Users USD Million (2021-2026)
  • Table 487. Mexico Flu RNA Vaccines, by Sales USD Million (2021-2026)
  • Table 488. Mexico Flu RNA Vaccines, by Usages USD Million (2021-2026)
  • Table 489. Flu RNA Vaccines Sales: by Application(K Units)
  • Table 490. Flu RNA Vaccines Sales Hospitals , by Region K Units (2021-2026)
  • Table 491. Flu RNA Vaccines Sales Emergency Departments , by Region K Units (2021-2026)
  • Table 492. Flu RNA Vaccines Sales Clinics , by Region K Units (2021-2026)
  • Table 493. Flu RNA Vaccines Sales Others , by Region K Units (2021-2026)
  • Table 494. Flu RNA Vaccines Sales: by End Users(K Units)
  • Table 495. Flu RNA Vaccines Sales Adults , by Region K Units (2021-2026)
  • Table 496. Flu RNA Vaccines Sales Kids , by Region K Units (2021-2026)
  • Table 497. Flu RNA Vaccines Sales: by Sales(K Units)
  • Table 498. Flu RNA Vaccines Sales Hospitals , by Region K Units (2021-2026)
  • Table 499. Flu RNA Vaccines Sales Retail Pharmacy Stores , by Region K Units (2021-2026)
  • Table 500. Flu RNA Vaccines Sales: by Usages(K Units)
  • Table 501. Flu RNA Vaccines Sales Infectious Disease , by Region K Units (2021-2026)
  • Table 502. Flu RNA Vaccines Sales Flu , by Region K Units (2021-2026)
  • Table 503. Flu RNA Vaccines Sales Others , by Region K Units (2021-2026)
  • Table 504. South America Flu RNA Vaccines Sales, by Country K Units (2021-2026)
  • Table 505. South America Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 506. South America Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 507. South America Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 508. South America Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 509. Brazil Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 510. Brazil Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 511. Brazil Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 512. Brazil Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 513. Argentina Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 514. Argentina Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 515. Argentina Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 516. Argentina Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 517. Chile Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 518. Chile Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 519. Chile Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 520. Chile Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 521. Rest of South America Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 522. Rest of South America Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 523. Rest of South America Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 524. Rest of South America Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 525. Asia Pacific Flu RNA Vaccines Sales, by Country K Units (2021-2026)
  • Table 526. Asia Pacific Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 527. Asia Pacific Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 528. Asia Pacific Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 529. Asia Pacific Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 530. China Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 531. China Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 532. China Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 533. China Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 534. Japan Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 535. Japan Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 536. Japan Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 537. Japan Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 538. India Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 539. India Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 540. India Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 541. India Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 542. South Korea Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 543. South Korea Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 544. South Korea Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 545. South Korea Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 546. Singapore Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 547. Singapore Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 548. Singapore Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 549. Singapore Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 550. Indonesia Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 551. Indonesia Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 552. Indonesia Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 553. Indonesia Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 554. Thailand Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 555. Thailand Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 556. Thailand Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 557. Thailand Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 558. Australia Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 559. Australia Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 560. Australia Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 561. Australia Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 562. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 563. Rest of Asia-Pacific Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 564. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 565. Rest of Asia-Pacific Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 566. Europe Flu RNA Vaccines Sales, by Country K Units (2021-2026)
  • Table 567. Europe Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 568. Europe Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 569. Europe Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 570. Europe Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 571. Germany Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 572. Germany Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 573. Germany Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 574. Germany Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 575. France Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 576. France Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 577. France Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 578. France Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 579. Italy Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 580. Italy Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 581. Italy Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 582. Italy Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 583. United Kingdom Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 584. United Kingdom Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 585. United Kingdom Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 586. United Kingdom Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 587. Netherlands Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 588. Netherlands Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 589. Netherlands Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 590. Netherlands Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 591. Spain Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 592. Spain Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 593. Spain Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 594. Spain Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 595. Sweden Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 596. Sweden Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 597. Sweden Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 598. Sweden Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 599. Belgium Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 600. Belgium Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 601. Belgium Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 602. Belgium Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 603. Finland Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 604. Finland Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 605. Finland Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 606. Finland Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 607. Denmark Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 608. Denmark Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 609. Denmark Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 610. Denmark Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 611. Russia Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 612. Russia Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 613. Russia Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 614. Russia Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 615. Rest of Europe Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 616. Rest of Europe Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 617. Rest of Europe Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 618. Rest of Europe Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 619. MEA Flu RNA Vaccines Sales, by Country K Units (2021-2026)
  • Table 620. MEA Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 621. MEA Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 622. MEA Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 623. MEA Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 624. Middle East Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 625. Middle East Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 626. Middle East Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 627. Middle East Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 628. Africa Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 629. Africa Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 630. Africa Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 631. Africa Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 632. North America Flu RNA Vaccines Sales, by Country K Units (2021-2026)
  • Table 633. North America Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 634. North America Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 635. North America Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 636. North America Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 637. United States Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 638. United States Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 639. United States Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 640. United States Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 641. Canada Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 642. Canada Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 643. Canada Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 644. Canada Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 645. Mexico Flu RNA Vaccines Sales, by Application K Units (2021-2026)
  • Table 646. Mexico Flu RNA Vaccines Sales, by End Users K Units (2021-2026)
  • Table 647. Mexico Flu RNA Vaccines Sales, by Sales K Units (2021-2026)
  • Table 648. Mexico Flu RNA Vaccines Sales, by Usages K Units (2021-2026)
  • Table 649. Research Programs/Design for This Report
  • Table 650. Key Data Information from Secondary Sources
  • Table 651. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Flu RNA Vaccines: by Application USD Million (2015-2020)
  • Figure 5. Global Flu RNA Vaccines: by End Users USD Million (2015-2020)
  • Figure 6. Global Flu RNA Vaccines: by Sales USD Million (2015-2020)
  • Figure 7. Global Flu RNA Vaccines: by Usages USD Million (2015-2020)
  • Figure 8. South America Flu RNA Vaccines Share (%), by Country
  • Figure 9. Asia Pacific Flu RNA Vaccines Share (%), by Country
  • Figure 10. Europe Flu RNA Vaccines Share (%), by Country
  • Figure 11. MEA Flu RNA Vaccines Share (%), by Country
  • Figure 12. North America Flu RNA Vaccines Share (%), by Country
  • Figure 13. Global Flu RNA Vaccines: by Application K Units (2015-2020)
  • Figure 14. Global Flu RNA Vaccines: by End Users K Units (2015-2020)
  • Figure 15. Global Flu RNA Vaccines: by Sales K Units (2015-2020)
  • Figure 16. Global Flu RNA Vaccines: by Usages K Units (2015-2020)
  • Figure 17. South America Flu RNA Vaccines Share (%), by Country
  • Figure 18. Asia Pacific Flu RNA Vaccines Share (%), by Country
  • Figure 19. Europe Flu RNA Vaccines Share (%), by Country
  • Figure 20. MEA Flu RNA Vaccines Share (%), by Country
  • Figure 21. North America Flu RNA Vaccines Share (%), by Country
  • Figure 22. Global Flu RNA Vaccines share by Players 2020 (%)
  • Figure 23. Global Flu RNA Vaccines share by Players (Top 3) 2020(%)
  • Figure 24. Global Flu RNA Vaccines share by Players (Top 5) 2020(%)
  • Figure 25. BCG Matrix for key Companies
  • Figure 26. Alnylam Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Alnylam Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Arbutus Biopharma Corp. (Canada) Revenue, Net Income and Gross profit
  • Figure 29. Arbutus Biopharma Corp. (Canada) Revenue: by Geography 2020
  • Figure 30. Arrowhead Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Arrowhead Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 32. BioNTech AG (Germany) Revenue, Net Income and Gross profit
  • Figure 33. BioNTech AG (Germany) Revenue: by Geography 2020
  • Figure 34. CureVac AG (Germany) Revenue, Net Income and Gross profit
  • Figure 35. CureVac AG (Germany) Revenue: by Geography 2020
  • Figure 36. Dicerna Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 37. Dicerna Pharmaceuticals, Inc. (United States) Revenue: by Geography 2020
  • Figure 38. Regulus Therapeutics, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 39. Regulus Therapeutics, Inc. (United States) Revenue: by Geography 2020
  • Figure 40. Marina Biotech, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 41. Marina Biotech, Inc (United States) Revenue: by Geography 2020
  • Figure 42. Global Flu RNA Vaccines: by Application USD Million (2021-2026)
  • Figure 43. Global Flu RNA Vaccines: by End Users USD Million (2021-2026)
  • Figure 44. Global Flu RNA Vaccines: by Sales USD Million (2021-2026)
  • Figure 45. Global Flu RNA Vaccines: by Usages USD Million (2021-2026)
  • Figure 46. South America Flu RNA Vaccines Share (%), by Country
  • Figure 47. Asia Pacific Flu RNA Vaccines Share (%), by Country
  • Figure 48. Europe Flu RNA Vaccines Share (%), by Country
  • Figure 49. MEA Flu RNA Vaccines Share (%), by Country
  • Figure 50. North America Flu RNA Vaccines Share (%), by Country
  • Figure 51. Global Flu RNA Vaccines: by Application K Units (2021-2026)
  • Figure 52. Global Flu RNA Vaccines: by End Users K Units (2021-2026)
  • Figure 53. Global Flu RNA Vaccines: by Sales K Units (2021-2026)
  • Figure 54. Global Flu RNA Vaccines: by Usages K Units (2021-2026)
  • Figure 55. South America Flu RNA Vaccines Share (%), by Country
  • Figure 56. Asia Pacific Flu RNA Vaccines Share (%), by Country
  • Figure 57. Europe Flu RNA Vaccines Share (%), by Country
  • Figure 58. MEA Flu RNA Vaccines Share (%), by Country
  • Figure 59. North America Flu RNA Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Alnylam Pharmaceuticals, Inc. (United States)
  • Arbutus Biopharma Corp. (Canada)
  • Arrowhead Pharmaceuticals, Inc. (United States)
  • BioNTech AG (Germany)
  • CureVac AG (Germany)
  • Dicerna Pharmaceuticals, Inc. (United States)
  • Regulus Therapeutics, Inc. (United States)
  • Marina Biotech, Inc (United States)
Additional players considered in the study are as follows:
Pfizer (United States) , Moderna (United States) , GlaxoSmithKline (United Kingdom) , Translate Bio (United States)`
Select User Access Type

Key Highlights of Report


Aug 2021 217 Pages 84 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Flu RNA Vaccines Market Quantitative research analysis
Global Flu RNA Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Flu RNA Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Linezolid Drug Comprehensive Study by Application (Complex Skin or Skin Soft Tissue Infection (SSTI), Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Vancomycin-Resistant Enter...
$ 3750
Gossypol Drugs Comprehensive Study by Form (Tablet, Capsule, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Online Third-Party Sales) Players and Region - Global Market Outlook to 2...
$ 3500
Rare Dermatological Disease Treatment Comprehensive Study by Treatment (Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, Others), Indication (Systemic Sclerosis...
$ 3450
Liquid Filled Hard Capsule Comprehensive Study by Application (Drugs, Vitamins & Mineral, Amino Acids, Peptides & Proteins, Lipids, Others), End Users (Pharmaceutical & Biopharmaceutical Companies, N...
$ 3650
Viral Vaccine Comprehensive Study by Type (Inactivated Vaccine, Live-attenuated Vaccine, Viral vector Vaccine, Nucleic acid Vaccine, Others), Disease (Pneumococcal Disease, DTP, Influenza, HPV, Menin...
$ 3750
Metformin Hydrochloride API Comprehensive Study by Type (Metformin HCL, Metformin DC, Others), Sales Channels (Direct Sales, In-Direct Sales), Grade (IP, EP, BP, USP) Players and Region - Global Mark...
$ 3500